Results 121 to 130 of about 319,594 (315)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

open access: yesMolecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak   +10 more
wiley   +1 more source

the Periodical Fall 2022

open access: yes, 2022
Vol. 9, Issue 2 of the Periodical features information about STEM departments fall outing, chemistry graduates, student missions, and department happenings.https://knowledge.e.southern.edu/theperiodical/1013/thumbnail ...
Southern Adventist University
core  

Interpreting the effects of DNA polymerase variants at the structural level

open access: yesMolecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi   +7 more
wiley   +1 more source

Periodical Room

open access: yes, 1980
Periodical room on the 1st floor of Welch Hall, circa 1980s Courtesy of the Rockefeller Archive Centerhttps://digitalcommons.rockefeller.edu/welch-hall/1017/thumbnail ...
The Rockefeller University
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Chronological framework of the Ailaoshan metamorphic belt, southeastern Tibet: implications for Cenozoic tectonothermal evolution

open access: yesAll Earth
The response mechanism of the southeastern Tibet Plateau to the Indian-Eurasian collision is still controversial. The widely distributed shear systems in the Sanjiang area especially Ailaoshan-Red River shear system contribute a window to understand the ...
Xiao-Fei Guo, Qing-Long Wang
doaj   +1 more source

Periodical Reviews, 400-1100

open access: yes, 2015
Review of periodical literature for the year ...
Costen, Michael D
core  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Periodicity and ultimate periodicity of D0L systems

open access: yesTheoretical Computer Science, 1991
The paper considers periodic and ultimately periodic DOL systems see e.g. \textit{T. Head} and \textit{B. Lando} [Periodic DOL languages, Theor. Comput. Sci. 46, 83-89 (1986; Zbl 0628.68058)], \textit{T. Harju} and \textit{M. Linna} [RAIRO, Inf. Theoret. 20, 47-54 (1986; Zbl 0608.68065)] and \textit{J. J. Pansiot} [RAIRO Inf. Theoret.
openaire   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy